Viewing Study NCT05209620


Ignite Creation Date: 2025-12-25 @ 4:25 AM
Ignite Modification Date: 2025-12-26 @ 3:29 AM
Study NCT ID: NCT05209620
Status: RECRUITING
Last Update Posted: 2025-04-23
First Post: 2021-12-26
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma
Sponsor: Henan Cancer Hospital
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Central Nervous System Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Central Nervous System Lymphoma View
None BTK inhibitor View
None Relapsed and Refractory View